Literature DB >> 20418788

Aberrant DNA methylation in malignant melanoma.

Carolina Schinke1, Yongkai Mo, Yiting Yu, Kathy Amiri, Jeff Sosman, John Greally, Amit Verma.   

Abstract

Malignant melanoma remains one of the most deadly human cancers with no effective cures for metastatic disease. The poor efficacy of current therapy in advanced melanoma highlights the need for better understanding of molecular mechanisms contributing to the disease. Recent work has shown that epigenetic changes, including aberrant DNA methylation, lead to alterations in gene expression and are as important in the development of malignant melanoma as the specific and well-characterized genetic events. Reversion of these methylation patterns could thus lead to a more targeted therapy and are currently under clinical investigation. The purpose of this review is to compile recent information on aberrant DNA methylation of melanoma, to highlight key genes and molecular pathways in melanoma development, which have been found to be epigenetically altered and to provide insight as to how DNA methylation might serve as targeted treatment option as well as a molecular and prognostic marker in malignant melanoma.

Entities:  

Mesh:

Year:  2010        PMID: 20418788      PMCID: PMC3026062          DOI: 10.1097/CMR.0b013e328338a35a

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  115 in total

1.  DNA methyltransferase Dnmt1 associates with histone deacetylase activity.

Authors:  F Fuks; W A Burgers; A Brehm; L Hughes-Davies; T Kouzarides
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

2.  Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.

Authors:  J F Costello; M C Frühwald; D J Smiraglia; L J Rush; G P Robertson; X Gao; F A Wright; J D Feramisco; P Peltomäki; J C Lang; D E Schuller; L Yu; C D Bloomfield; M A Caligiuri; A Yates; R Nishikawa; H Su Huang; N J Petrelli; X Zhang; M S O'Dorisio; W A Held; W K Cavenee; C Plass
Journal:  Nat Genet       Date:  2000-02       Impact factor: 38.330

Review 3.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.

Authors:  Adam R Karpf; Amy W Lasek; Ted O Ririe; Adrianne N Hanks; Douglas Grossman; David A Jones
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

5.  Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.

Authors:  Mia Spugnardi; Stella Tommasi; Reinhard Dammann; Gerd P Pfeifer; Dave S B Hoon
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

6.  DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.

Authors:  M Okano; D W Bell; D A Haber; E Li
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

7.  A systematic profile of DNA methylation in human cancer cell lines.

Authors:  Maria F Paz; Mario F Fraga; Sonia Avila; Mingzhou Guo; Marina Pollan; James G Herman; Manel Esteller
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

8.  Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells.

Authors:  Charles De Smet; Axelle Loriot; Thierry Boon
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.

Authors:  Dave S B Hoon; Mia Spugnardi; Christine Kuo; Sharon K Huang; Donald L Morton; Bret Taback
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

10.  Phase I trial of continuous infusion 5-aza-2'-deoxycytidine.

Authors:  A Aparicio; C A Eads; L A Leong; P W Laird; E M Newman; T W Synold; S D Baker; M Zhao; J S Weber
Journal:  Cancer Chemother Pharmacol       Date:  2003-02-27       Impact factor: 3.333

View more
  42 in total

Review 1.  Epigenetic biomarkers in skin cancer.

Authors:  Edward S Greenberg; Kelly K Chong; Kelly T Huynh; Ryo Tanaka; Dave S B Hoon
Journal:  Cancer Lett       Date:  2012-01-27       Impact factor: 8.679

2.  DNA methylome and transcriptome alterations and cancer prevention by triterpenoid ursolic acid in UVB-induced skin tumor in mice.

Authors:  Yuqing Yang; Ran Yin; Renyi Wu; Christina N Ramirez; Davit Sargsyan; Shanyi Li; Lujing Wang; David Cheng; Chao Wang; Rasika Hudlikar; Hsiao-Chen Kuo; Yaoping Lu; Ah-Ng Kong
Journal:  Mol Carcinog       Date:  2019-06-25       Impact factor: 4.784

3.  Triterpenoid corosolic acid modulates global CpG methylation and transcriptome of tumor promotor TPA induced mouse epidermal JB6 P+ cells.

Authors:  Rasika R Hudlikar; Davit Sargsyan; Renyi Wu; Shan Su; Meinizi Zheng; Ah-Ng Kong
Journal:  Chem Biol Interact       Date:  2020-03-03       Impact factor: 5.192

4.  DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.

Authors:  Goran Micevic; Viswanathan Muthusamy; William Damsky; Nicholas Theodosakis; Xiaoni Liu; Katrina Meeth; Emily Wingrove; Manjula Santhanakrishnan; Marcus Bosenberg
Journal:  Cell Rep       Date:  2016-02-25       Impact factor: 9.423

Review 5.  Epigenetic markers in melanoma.

Authors:  Weimin Guo; Ting Xu; Jonathan J Lee; George F Murphy; Christine G Lian
Journal:  Melanoma Manag       Date:  2015-11-24

6.  Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin.

Authors:  Anatoly Uzdensky; Svetlana Demyanenko; Mikhail Bibov; Svetlana Sharifulina; Oleg Kit; Yury Przhedetski; Viktoria Pozdnyakova
Journal:  Tumour Biol       Date:  2014-05-22

7.  Mitochondria DNA replication and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy.

Authors:  Shikha Tewari; Qing Zhong; Julia M Santos; Renu A Kowluru
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-24       Impact factor: 4.799

8.  The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.

Authors:  Cynthia C Smith; Baiquan Li; Juan Liu; Kie-Sok Lee; Laure Aurelian
Journal:  Cancer Invest       Date:  2011-07       Impact factor: 2.176

9.  CpG methyl-seq and RNA-seq epigenomic and transcriptomic studies on the preventive effects of Moringa isothiocyanate in mouse epidermal JB6 cells induced by the tumor promoter TPA.

Authors:  Chao Wang; Renyi Wu; Davit Sargsyan; Meinizi Zheng; Shanyi Li; Ran Yin; Shan Su; Ilya Raskin; Ah-Ng Kong
Journal:  J Nutr Biochem       Date:  2019-03-28       Impact factor: 6.048

10.  There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis.

Authors:  Rolf K Swoboda; Meenhard Herlyn
Journal:  Exp Dermatol       Date:  2013-03-12       Impact factor: 3.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.